A new trading day began on Monday, with Astrazeneca plc ADR (NASDAQ: AZN) stock price up 0.47% from the previous day of trading, before settling in for the closing price of $64.49. AZN’s price has ranged from $60.47 to $87.68 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 16.24% over the past five years. Meanwhile, its annual earnings per share averaged 12.30%. With a float of $3.10 billion, this company’s outstanding shares have now reached $3.10 billion.
Let’s look at the performance matrix of the company that is accounted for 89900 employees. In terms of profitability, gross margin is 78.24%, operating margin of 18.87%, and the pretax margin is 15.8%.
Astrazeneca plc ADR (AZN) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – General Industry. The insider ownership of Astrazeneca plc ADR is 0.03%, while institutional ownership is 16.25%.
Astrazeneca plc ADR (AZN) Performance Highlights and Predictions
In its latest quarterly report, released on 6/30/2024, the company reported earnings of 0.87 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to 17.72% growth over the previous five years of trading.
Astrazeneca plc ADR (NASDAQ: AZN) Trading Performance Indicators
Here are Astrazeneca plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.09. Likewise, its price to free cash flow for the trailing twelve months is 20.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.06, a number that is poised to hit 1.02 in the next quarter and is forecasted to reach 4.69 in one year’s time.
Technical Analysis of Astrazeneca plc ADR (AZN)
Astrazeneca plc ADR (NASDAQ: AZN) saw its 5-day average volume 13.17 million, a positive change from its year-to-date volume of 5.22 million. As of the previous 9 days, the stock’s Stochastic %D was 10.92%. Additionally, its Average True Range was 1.57.
During the past 100 days, Astrazeneca plc ADR’s (AZN) raw stochastic average was set at 5.84%, which indicates a significant decrease from 10.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.06% in the past 14 days, which was higher than the 22.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $76.61, while its 200-day Moving Average is $74.79. Nevertheless, the first resistance level for the watch stands at $65.10 in the near term. At $65.41, the stock is likely to face the second major resistance level. The third major resistance level sits at $65.61. If the price goes on to break the first support level at $64.59, it is likely to go to the next support level at $64.39. Assuming the price breaks the second support level, the third support level stands at $64.08.
Astrazeneca plc ADR (NASDAQ: AZN) Key Stats
With a market capitalization of 200.89 billion, the company has a total of 3,100,589K Shares Outstanding. Currently, annual sales are 45,811 M while annual income is 5,955 M. The company’s previous quarter sales were 12,938 M while its latest quarter income was 1,927 M.
